search
Back to results

Clinical Investigation of NMS Assist

Primary Purpose

Parkinson

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
NMS Assist
Sponsored by
University of Plymouth
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Parkinson focused on measuring Parkinson Disease, Self-Management, Telemedicine

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Willing and able to provide informed consent and comply with intervention requirements
  • 18 years or older
  • Be fluent in English
  • Not resident in a care or nursing home
  • Ambulant
  • Have compatible smartphone/data access
  • Normally under the care of the Parkinson's service in the participating organisation
  • Participant's HCP in the participating organisation consented to participate in the study

Exclusion Criteria:

  • Secondary cause of parkinsonism
  • Significant cognitive impairment or a diagnosis of Parkinson's disease dementia
  • Living in residential care facilities
  • Previous involvement in development or testing of the NMS Assist system
  • Significant comorbidity, which in the opinion of the chief investigator would preclude safe participation in the study or protocol compliance (e.g. life expectancy <6 months)
  • In a dependent/unequal relationship with anyone involved in the research or care teams

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    NMS Assist

    Arm Description

    NMS Assist provides a system of linking PwP, CPs, and healthcare providers (HCPs) to monitor and empower self-management of non-motor symptoms through the use of a mobile app and web portal.

    Outcomes

    Primary Outcome Measures

    Patient (and care partner) activation
    Patient Activation Measure (and caregiver version) will be used to evaluate their confidence, knowledge, and skills at non-motor symptom self-management

    Secondary Outcome Measures

    Presence of non-motor symptoms
    Measured using the Non-Motor Symptoms Questionnaire (NMSQ), patients tick 'yes' or 'no' for each symptom listed
    Frequency and severity of non-motor symptoms
    Measured using the Movement Disorder Society Non-Motor Symptoms Scale (MDS-NMS), where higher scores indicate greater frequency and/or severity
    Short-form self-assessment of functioning and well-being related to Parkinson's disease
    Measured using the short-form Parkinson's Disease Questionnaire (PDQ-8), patients indicate the frequency with which they experience certain issues
    Long-form self-assessment of functioning and well-being related to Parkinson's disease
    Measured using the long-form Parkinson's Disease Questionnaire PDQ-39, patients indicate the frequency with which they experience certain issues
    Carer well-being and quality of life
    Measured using the Parkinson Disease Questionnaire for care partners; care partners indicate the frequency with which they experience certain issues
    Health status
    Measured using the EQ-5D-5L; higher scores on the EQ-5D-5L descriptive system indicate worse health problems in the specific dimension whereas a high score in the EQ VAS indicates better health on the day of the questionnaire
    Mental well-being
    Measured using the Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS); Scores range from 14 to 70 (on the 14 item version) and higher scores indicate greater positive mental wellbeing
    Adverse events
    Adverse Event Reporting
    Clinical safety
    Record of any events missed
    Healthcare contacts
    Number of PwP-initiated contacts with healthcare team (through the 'request healthcare contact' feature) and the number of HCP-initiated contacts (due to system flagging PwP based on PwP and CP-reported outcomes), recorded by the system
    Technical and implementation issues
    Technical issues identified from the system use data and by participants and process measures relating to service delivery
    Quantitative usability
    System Usability Scale, out of 100 with higher scores indicating better usability
    Acceptability
    Acceptability and usability feedback from semi-structured interviews
    System use and compliance
    Data collected via the system about users engagement with the system (e.g. number of times accessed, length of time accessed, features used)
    Engagement
    Qualitative feedback from participants
    Costs
    Cost analysis will be used to examine the factors impacting costs for implementing the system

    Full Information

    First Posted
    June 1, 2022
    Last Updated
    May 10, 2023
    Sponsor
    University of Plymouth
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05414071
    Brief Title
    Clinical Investigation of NMS Assist
    Official Title
    The Impact of a Digital Artificial Intelligence System on the Monitoring and Self-management of Non-motor Symptoms in People With Parkinson's
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    December 1, 2023 (Anticipated)
    Primary Completion Date
    March 1, 2025 (Anticipated)
    Study Completion Date
    March 1, 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Plymouth

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Parkinson's can cause a wide range of non-motor symptoms (NMS), including pain and problems with mental health, memory and sleep. These affect the quality of life of people with Parkinson's (PwP) and their care partners (CP). If these issues are not recognised and managed quickly, they can result in escalating problems. Many PwP are unsure of the extent and variety of the NMS and how simple adjustments at home could improve them. We have developed a digital system, NMS Assist, to help PwP monitor their non-motor symptoms and develop skills to self-manage them. Such a tool needs to be simple to use, safe and effective. We will ask 60 PwP, CP and members of their Parkinson's healthcare team to use NMS Assist for 12 months, and we will monitor how they use the tool. PwP and CPs will be asked if they feel more knowledgeable and confident to manage their own symptoms whilst being better able to discuss a problem with their healthcare professional. A smaller group of the participants will discuss their experiences in more detail to help pinpoint aspects that work well and those needing adjustment and development. Members of the healthcare team will be asked to assess any improvement in communication with PwP and CPs. It is thought that the use of this system will result in improved quality of life and increased knowledge and confidence for managing symptoms while safely reducing the time spent by health care professionals on manageable non-motor symptoms.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Parkinson
    Keywords
    Parkinson Disease, Self-Management, Telemedicine

    7. Study Design

    Primary Purpose
    Supportive Care
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    60 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    NMS Assist
    Arm Type
    Experimental
    Arm Description
    NMS Assist provides a system of linking PwP, CPs, and healthcare providers (HCPs) to monitor and empower self-management of non-motor symptoms through the use of a mobile app and web portal.
    Intervention Type
    Device
    Intervention Name(s)
    NMS Assist
    Intervention Description
    The system enables people with Parkinson's and their care partners to complete questionnaires about symptoms and burden and share that information with their care team. They can also access self-help resources and materials about managing non-motor symptoms. Healthcare providers have a dashboard that flags any worsening symptoms or discrepancies between PwP and CP reports, enabling their to prioritise care and quickly see the status of their patients. The system also enables PwP or CPs to request healthcare contact.
    Primary Outcome Measure Information:
    Title
    Patient (and care partner) activation
    Description
    Patient Activation Measure (and caregiver version) will be used to evaluate their confidence, knowledge, and skills at non-motor symptom self-management
    Time Frame
    Assessed monthly for 12 months
    Secondary Outcome Measure Information:
    Title
    Presence of non-motor symptoms
    Description
    Measured using the Non-Motor Symptoms Questionnaire (NMSQ), patients tick 'yes' or 'no' for each symptom listed
    Time Frame
    Measured at patients' discretion throughout intervention (12 months)
    Title
    Frequency and severity of non-motor symptoms
    Description
    Measured using the Movement Disorder Society Non-Motor Symptoms Scale (MDS-NMS), where higher scores indicate greater frequency and/or severity
    Time Frame
    Measured at baseline, 6, and 12 months
    Title
    Short-form self-assessment of functioning and well-being related to Parkinson's disease
    Description
    Measured using the short-form Parkinson's Disease Questionnaire (PDQ-8), patients indicate the frequency with which they experience certain issues
    Time Frame
    Measured at patients' discretion throughout intervention (12 months)
    Title
    Long-form self-assessment of functioning and well-being related to Parkinson's disease
    Description
    Measured using the long-form Parkinson's Disease Questionnaire PDQ-39, patients indicate the frequency with which they experience certain issues
    Time Frame
    Measured at baseline, 6, and 12 months
    Title
    Carer well-being and quality of life
    Description
    Measured using the Parkinson Disease Questionnaire for care partners; care partners indicate the frequency with which they experience certain issues
    Time Frame
    Measured at care partners' discretion throughout intervention (12 months)
    Title
    Health status
    Description
    Measured using the EQ-5D-5L; higher scores on the EQ-5D-5L descriptive system indicate worse health problems in the specific dimension whereas a high score in the EQ VAS indicates better health on the day of the questionnaire
    Time Frame
    Measured at baseline, 6, and 12 months
    Title
    Mental well-being
    Description
    Measured using the Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS); Scores range from 14 to 70 (on the 14 item version) and higher scores indicate greater positive mental wellbeing
    Time Frame
    Measured at baseline, 6, and 12 months
    Title
    Adverse events
    Description
    Adverse Event Reporting
    Time Frame
    Throughout 12 months
    Title
    Clinical safety
    Description
    Record of any events missed
    Time Frame
    Throughout 12 months
    Title
    Healthcare contacts
    Description
    Number of PwP-initiated contacts with healthcare team (through the 'request healthcare contact' feature) and the number of HCP-initiated contacts (due to system flagging PwP based on PwP and CP-reported outcomes), recorded by the system
    Time Frame
    Throughout 12 months
    Title
    Technical and implementation issues
    Description
    Technical issues identified from the system use data and by participants and process measures relating to service delivery
    Time Frame
    Throughout 12 months
    Title
    Quantitative usability
    Description
    System Usability Scale, out of 100 with higher scores indicating better usability
    Time Frame
    6 and 12 months
    Title
    Acceptability
    Description
    Acceptability and usability feedback from semi-structured interviews
    Time Frame
    3, 6, and 12 months
    Title
    System use and compliance
    Description
    Data collected via the system about users engagement with the system (e.g. number of times accessed, length of time accessed, features used)
    Time Frame
    Throughout 12 months
    Title
    Engagement
    Description
    Qualitative feedback from participants
    Time Frame
    3, 6, and 12 months
    Title
    Costs
    Description
    Cost analysis will be used to examine the factors impacting costs for implementing the system
    Time Frame
    Throughout 12 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Willing and able to provide informed consent and comply with intervention requirements 18 years or older Be fluent in English Not resident in a care or nursing home Ambulant Have compatible smartphone/data access Normally under the care of the Parkinson's service in the participating organisation Participant's HCP in the participating organisation consented to participate in the study Exclusion Criteria: Secondary cause of parkinsonism Significant cognitive impairment or a diagnosis of Parkinson's disease dementia Living in residential care facilities Previous involvement in development or testing of the NMS Assist system Significant comorbidity, which in the opinion of the chief investigator would preclude safe participation in the study or protocol compliance (e.g. life expectancy <6 months) In a dependent/unequal relationship with anyone involved in the research or care teams

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided
    IPD Sharing Plan Description
    Data belongs to the study sponsor (the University of Plymouth) and deidentified data will be made available in line with the data sharing policy developed with Parkinson's UK and PPI representatives.
    Citations:
    PubMed Identifier
    36155396
    Citation
    Meinert E, Milne-Ives M, Chaudhuri KR, Harding T, Whipps J, Whipps S, Carroll C. The Impact of a Digital Artificial Intelligence System on the Monitoring and Self-management of Nonmotor Symptoms in People With Parkinson Disease: Proposal for a Phase 1 Implementation Study. JMIR Res Protoc. 2022 Sep 26;11(9):e40317. doi: 10.2196/40317.
    Results Reference
    derived

    Learn more about this trial

    Clinical Investigation of NMS Assist

    We'll reach out to this number within 24 hrs